Stryker reported strong organic sales growth of 4.7% in Q1 2021 compared to Q1 2019, driven by robust performances in Mako, Neurotech, and Medical franchises. Despite the impact of reduced elective procedures, hip and knee businesses showed improvement, with mid-single-digit growth in April 2021 compared to April 2019. The integration of Wright Medical progressed well, with combined trauma and extremities business expected to deliver mid-single-digit growth for the full year. Adjusted net earnings per diluted share guidance has been elevated to $9.05-$9.30, reflecting improved Wright Medical sales and disciplined cost management. The company reiterates its organic net sales growth target of 8%-10% for 2021, driven by a recovery in elective procedures and ongoing contributions from its diversified business model.